. A comparison of the MICs and MLCs of ojloxacin, ciprojloxacin, enoxacin and norjloxacin against C. trachomatis Ofloxacin Ciprofloxacin Enoxacin Norfloxacin enoxacin and norfloxacin on inclusion development and infectivity. The MICs and MLCs of these drugs are compared in Table 1 . There was considerable variation in the sensitivity of C. trachomatis to these quinolones, which may reflect their varying ability to penetrate eukaryotic cells. However, at effective concentrations, the action of each drug was lethal, i.e. infectivity was not affected by further incubation after withdrawal of the drug, so there was little or no difference between the MIC and MLC.
Additional tests in vitro, summarized in Table 2 , were carried out on ofloxacin, the most active of the quinolones tested against chlamydia. Exposure of infected monolayers for the first 24h of the cycle (when RB replication predominantly occurs) (schedule D) was almost as effective as exposure throughout one cycle (48h) or longer (96h) (schedules A and B), and little recovery occurred when monolayers were reincubated in drug-free medium for a further 72h (schedule E). AS might have been predicted, exposure of monolayers to ofloxacin for the second 24 h of the cycle (when maturation rather than replication of RBs occurs) had little effect (schedules F and G). An unexpected finding, however, was the dramatic reduction in infectivity which occurred after prolonged (72 h) exposure to ofloxacin after the majority of RB replication had taken place (schedule H). This suggested that ofloxacin was acting against some enzyme function which was essential for survival of non-replicating intracellular chlamydia. Such action may be particularly relevant for treatment of naturally occurring infections, which are frequently characterized by persistent quiescent infection (Oriel & Ridgway, 1982) .
These studies in vitro suggest that a quinolone active at concentrations which can be achieved in serum would act quickly against chlamydia, so that only a short course of treatment would be required (< 7 days). Of the drugs tested, ofloxacin (MLC 1 mg/l) appeared to have most therapeutic potential. This coincides with the findings of Table 2 . Schedules in vitro used to investigate the effect of ojloxacin on infectivity of chlamydia-infected monolayers McCoy cell monolayers were inoculated with approx. lo3 inclusion-forming units (IFU) of C. trachomatis, then incubated for various times with (+) and without (-) ofloxacin. Infectivity was assessed by passage into drug-free monolayers at the end of the incubation period. The lethal concentration of ofloxacin in each schedule was defined as the minimum concentration which destroyed all IFU in the monolayers; control infected monolayers, incubated without ofloxacin throughout each schedule, yielded at least lo5 IFU. (Van Roosbroeck, 1984) . Ofloxacin serum levels of 1 mg/l can be achieved and maintained in humans (Saito & Tomizawa, 1983) , so clinical trials of its action against naturally occurring chlamydia1 infections will be of interest. Ofloxacin may also provide a useful tool for gaining insights into essential DNA metabolism in nonreplicating intracellular chlamydia that is controlled by topoisomerases. The introduction of nalidixic acid in 1962 was soon followed by papers on its use for treatment of urinary tract infection (Lishman & Swinney, 1963) . At that time there was an urgent need for anti-bacterial agents active against sulphonamide-resistant bacteria especially in urinary tract infections and associated bacteraemias. Lishman & Swinney found that nalidixic acid was very satisfactory for treatment of Gram-negative urinary infections, although subsequent workers would have disagreed with their finding that pseudomonas infections were cleared. Proteus infection often associated with a diseased urinary tract presented a particular problem for which it was hard to find an answer. Even in 1972, the use of intravenous nalidixic acid was being described for septicaemias associated with urinary tract infection by Economou et al. However, the intravenous preparation was not marketed, and the rapid development of resistance discouraged the use of a topical preparation. As nalidixic acid is significantly metabolized in the body, a high dose (4 g per day) is required to provide therapeutic activity in the urine. Such high doses may account for the toxic side-effects, which, in addition to the gastrointestinal upsets and allergies that may be produced by any antibiotic, include occasional neurotoxicity: headaches, visual disturbances and convulsions have been reported, such that the drug should be avoided in patients with pre-existing mental instability, epilepsy and cerebral arteriosclerosis (Kucers & Bennet, 1979) . Because of the low serum levels attained nalidixic acid has thus been regarded as a 'urinary antiseptic'; however, it is also active in the gut. Moorhead & Parry (1965) showed its use for treatment of Shigella s o m e diarrhoea, and Dupont et al. (1978) suggested it for travellers' diarrhoea. In general these are not diseases that require antibiotic treatment, although occasional cases may warrant it. Although bacterial resistance to nalidixic acid does occur, it is not plasmid-mediated, so that it is relatively rare and may occur in isolation. A survey of inpatients at Addenbrooke's hospital some years ago revealed approx. 20 isolates of Escherichia coli that were only resistant to nalidixic acid, and in at least two patients these strains were recovered regularly over some years.
Nalidixic acid has a relatively simple structure that is readily modified; indeed Albrecht (1977) listed over 1000 variants, few of which showed much improvement, although some unusual ones included links with other anti-microbial agents such as nitrofurantoin and ampicillin. However, it is only in the last few years that there has been a marked increase in products with 100-1000 times greater activity than nalidixic acid, so that Gram-positive bacteria, and some of the more resistant Gram-negatives such as Pseudomonas aeruginosa, come within the therapeutic range. Even nalidixic acid-resistant strains of the normally susceptible enterobacteria come within striking distance. The hope for the new drugs therefore is that of use of lower dosage treatment for nalidixic acid-susceptible strains, and of the ability to use higher doses for infections with more resistant microbes, or in more inaccessible places. Pharmacokinetic studies have produced some interesting clues as to the clinical use of the group: notably variability of metabolism, the concentration in some tissues (Wise, 1984) , high levels in bile, and the penetration into macrophages (Easmon & Crane, 1985) . Clinical results outside of those on urinary tract infection are still being evaluated. This short review will start with a description of a trial of norfloxacin for urinary tract infection in a general practise study (Newsom et al., 1983 ; Sabbaj e t al., 1985), then discuss some findings from a trial of ciprofloxacin in urinary tract infection in the elderly, for gut sterilization, and for systemic infection (Newsom et al., 1 9 8 5~) . The other possible uses of quinolones will then be summarized.
Genito-urinary tract infection
The international multi-centre trial of norfloxacin for uncomplicated urinary tract infection showed that norfloxacin was as effective as cotrimoxazole (97-93% eradication). A prerequisite was the exclusion of patients with infections due to organisms showing resistance to cotrimoxazole, currently 8-1 1 YO, so biasing the results against norfloxacin to which virtually no isolates are resistant. An important finding was that norfloxacin gave significantly fewer side effects even though the rather high dose of 400mg twice daily for 7 days was used. Indeed seven patients on cotrimoxazole had to stop treatment because of side-effects. Thus for uncomplicated urinary tract infection this drug seems very satisfactory, but it must be borne in mind that spontaneous cure rates of 50% have been noted. Table 1 shows the results of laboratory tests on our patients (Newsom, 1984) . The infecting organisms appeared much less susceptible when tested in urine, and the anti-bacterial activity found in the patient's urine was much less when tested using urine as a culture medium than when tested in broth. Nonetheless the patient's organisms were eradicated. Indeed, according to Crumplin & Smith (1975) high urinary activity could be counter-productive by inhibition of protein synthesis in the bacteria with consequent reduction of bactericidal activity. During our trial we noted that three of the four patients with candida superinfection were in the cotrimoxazole group. As norfloxacin has the wider Although the general practise study used a fairly long course and high dosage (400mg), studies with other agents have shown that shorter courses are satisfactory for uncomplicated urinary tract infections. A second trial (S. W. B. Newsom, J. Matthews & R. Murphy, unpublished work) used 100 mg of ciprofloxacin twice daily for 5 days for bacteriuria in the elderly. In this trial ciprofloxacin was shown to work better than trimethoprim. As these patients were in hospital more follow up was possible and we were able to measure urinary and faecal levels of drug by a bioassay both during and after treatment. Table 2 shows that levels of anti-bacterial activity above the inhibitory level required for the infecting organisms was found in urine for up to 5 days after stopping treatment. The logical extension of this is that single-dose therapy might in fact provide a long enough exposure of the urinary tract to the drugs, and Graeff e t al. (1985) found that a single dose of 250mg of ciprofloxacin was adequate to treat urinary tract infections in gynaecological patients.
The Japanese literature on use of norfloxacin for complex urinary tract infections was summarized by Holmes & Brogden (1985) and is less encouraging. Overall a 50% success rate was reported, but on further analysis this included patients with in-dwelling catheters (who would not normally be treated with antibiotics in the U.K.), and immediately post-prostatectomy. Williams & Gruneberg (1985) reported an 86% cure rate in hospitalized patients Table 2 . Persistence of cipro-oxacin in urine after stopping therapy Results are shown as the amount of ciprofloxacin (mg/l) present in random samples of urine on the 5 days after stopping therapy in eight patients. with urinary tract infection treated with 100 or250mg of ciprofloxacin twice daily for 5 days. These included infections with organisms resistant to more conventional antibiotics such as Pseudomonas aeruginosa.
The high activity in vitro against the gonococcus has been vindicated in trials of quinolones for gonorrhoea. Crider et al. (1984) reported 100% success with singledose therapy using norfloxacin for penicillin-resistant infections in sailors in the Phillipines. Hopefully, these drugs might also be used for prostatitis, and for chlamydial infections. Another possible use would be for longterm suppressive therapy of urinary infection.
Use for bowel decontamination
High levels were found in faeces during therapy for urinary tract infection with ciprofloxacin, and significant levels were still present 5 days later ( Fig. 1; Newsom et  al., 1985~) . The aerobic faecal flora of these patients was reduced to enterococci and occasionally candidas, while the anaerobes were little affected. The subsequent occurrence of an outbreak of gentamicin-resistant klebsiella infections in an orthopaedic ward prompted the use of nalidixic acid versus ciprofloxacin in a randomized trial to try and stop the spread of infection via faecal carriers. Nalidixic acid worked in eight116 patients, and ciprofloxacin in 13/17. Two nalidixic failures were due to resistant strains ab initio, and a third developed resistance during treatment. The strains from three ciprofloxacin failures recurred in smaller numbers after temporary eradication and all remained susceptible.
These findings suggest that quinolones might be useful for the prevention of bacteraemia in neutropenic patients by gut decontamination, and several trials are currently under way; early reports from these are encouraging. As general policy is not to use antibiotics for diarrhoea1 disease, the undoubted efficacy of quinolones in the gut may not be needed too often. A particular problem is eradication of salmonellas in the immunosuppressed. A 6 week course of norfloxacin was used in a patient with myeloma suffering from continued Salmonella typhimurium infection; her gentamicincarbenicillin-resistant pseudomonas urinary infection was also cleared. Hudson et al. (1985) reported the eradication of Salmonella typhimurium using 28 days of ciprofloxacin treatment. An international trial of norfloxacin for acute bacterial gastro-enteritis showed that pathogens were eliminated in 100% of patients by use of 1200mg daily for 5 days (Holmes & Brogden, 1985) . As well as salmonellas and shigellas, campylobacters and vibrios respond to quinolones. Clostridium diflcile is relatively resistant (Newsom et al. 1985b ), but so far we have only encountered one infection with this organism despite monitoring the faeces in 50 patients on ciprofloxacin.
Respiratory tract infection
A tablet for chest infections is a popular goal for the drug company. The spectrum of the new quinolones covers some, but not all, of the common pathogens, the main exception being Streptococcus pneumoniae, for which inhibitory levels are marginal in terms of the concentrations of drug achievable in the lung and sputum. An important though restricted potential role is for the treatment of the pseudomonas lung infections that limit the life of adult cystic fibrosis patients and may be a problem in patients with bronchiestasis and advanced chronic bronchitis. Some success with ciprofloxacin treatment in patients with cystic fibrosis has been reported, while Roberts et al. (1984) demonstrated a good response in eight of nine patients with severe bronchiectasis. The quinolones also have good activity on the less common causes of pneumonia, the mycoplasmas and legionellas, and enough activity to assist in treatment of psittacosis (Winter et al., 1985) .
Systemic infections
Oral administration of the more potent quinolones has been enough to clear the bloodstream in septicaemias in neutropenic patients and associated with urinary tract infections. The anti-pseudomonas aspect means that abscesses or wound infections with pseudomonas as a genuine pathogen can also be treated. Skin and burns infections, especially where pseudomonas or staphylococci are implicated, might be expected to respond, and Desplaces et al. (1984) have reported on the successful use of quinolones for staphylococcal osteomyelitis, although in combination therapy. Intravenous preparations of ciprofloxacin and pefloxacin have been made available for clinical trial, and we used the former for the first time on a patient, a neonate with persistent Serratia septicaemia which was cleared by ciprofloxacin after failing to respond to piperacillin, cefotaxime then ceftazidime plus amikacin. Pefloxacin has been shown to penetrate into the cerebrospinal fluid. However, good alternatives already exist for meningitis so quinolones may not be needed, except perhaps as alternatives to rifampicin for clearance of meningococcal carriers.
Resistancelside efects
The development of resistance to the quinolones has been followed in the laboratory, where it occurs less frequently than with nalidixic acid. However, use for chest infection with less susceptible organisms may result in development of resistant strains (Roberts et al., 1985) , and one of our patients had their pseudomonas replaced with a ciprofloxacin-resistant Staphylococcus aureus. The side effects so far have not been as frequent or severe as with nalidixic acid, being mainly gut, or minor central nervous system, in type. However, enoxacin has been shown to interact with theophylline, so the two drugs should not be mixed, and long-term use of norfloxacin in two immunosuppressed patients was linked with tendinitis. As the drugs are potent anti-DNA compounds the worries about teratogenicity/malignancy must have been raised, but there is no evidence on this to cause concern at present.
